ROSUVASTATIN AND CHRONIC HEPATITIS C (LETTER TO EDITOR)

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

YOSHIDA ERIC M.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Hepatitis Monthly Year:2011 | Volume:11 | Issue:5 (34) Page(s): 384-385

Download Full-Text

View:

309

Download:

184

Cites:

Information Journal Paper

Title

ROSUVASTATIN AND CHRONIC HEPATITIS C (LETTER TO EDITOR)

Author(s)

YOSHIDA ERIC M. | Issue Writer Certificate

Keywords

ROSUVASTATIN

CHRONIC HEPATITIS C

INTERFERON

RIBAVIRIN

Abstract

The prospective randomized clinical trial of Malaguarnera and colleagues, published in the current issue of Hepatitis Monthly, investigates the potential role of a commercially available HMG Co-A reductase agent—ROSUVASTATIN (Crestor, Astra Zeneca) —in combination with non-pegylated INTERFERON and RIBAVIRIN in the treatment of CHRONIC HEPATITIS C (HCV). HMG Co-A reductase agents, commonly referred to as statins, are popular agents prescribed throughout the world, for their cholesterol lowering effects in order to reduce the risk of cardiovascular morbidity and mortality. They are well-recognized to improve liver biochemistry in dyslipidemic patients with non-alcoholic fatty liver disease (1); but recent reports have suggested that they may possess an antiviral effect on HCV independent of their lipid lowering activity. In an in vitro study (2), various statin agents were reported to have differing effects on HCV replication in combination with INTERFERON with fluvastatin (Lescol, Novartis) exhibiting the strongest anti-HCV activity, atorvastatin (Lipitor, Pfizer) had moderate activity whereas pravastatin (Pravachol, Bristol Myers Squibb) had no activity. Likewise, the combination of statins—specifically simvistatin and mevastatin—in combination with protease/polymerase inhibitor agents were found to clear HCV replicons from culture (3). It is interesting that this in vitro study also found that pravastatin exhibited no antiviral activity (3). Clinically, the experience of statin agents in the treatment of HCV has not been very well-studied and the reported outcomes have been interesting yet at times conflicting. Fluvastatin monotherapy was reported to produce a modest 1.75 log decrease in HCV viral load in HCV monoinfected patients (4).

Cites

No record.

References

No record.

Cite

APA: Copy

YOSHIDA, ERIC M.. (2011). ROSUVASTATIN AND CHRONIC HEPATITIS C (LETTER TO EDITOR). HEPATITIS MONTHLY, 11(5 (34)), 384-385. SID. https://sid.ir/paper/306397/en

Vancouver: Copy

YOSHIDA ERIC M.. ROSUVASTATIN AND CHRONIC HEPATITIS C (LETTER TO EDITOR). HEPATITIS MONTHLY[Internet]. 2011;11(5 (34)):384-385. Available from: https://sid.ir/paper/306397/en

IEEE: Copy

ERIC M. YOSHIDA, “ROSUVASTATIN AND CHRONIC HEPATITIS C (LETTER TO EDITOR),” HEPATITIS MONTHLY, vol. 11, no. 5 (34), pp. 384–385, 2011, [Online]. Available: https://sid.ir/paper/306397/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops